Autolus Therapeutics plc
corporate_fare Company Profile
Autolus Therapeutics plc (NASDAQ:AUTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for AUTL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for AUTL spans 10-Q, 8-K, S-3, 10-K.
Recent high-impact activity:
- Autolus Q3 10-Q: Revenue Doubles to $41.2M, Net Loss Narrows to $55.1M
- AUCATZYL Revenue Doubles to $41.2M; Full-Year Guidance Raised Above $150M
- Autolus' Obe-cel Wins FDA RMAT Designation for Lupus, Accelerating Path to Market
- Autolus Therapeutics Removes Going Concern Doubt, Reports Strong Q2 Revenue Growth & Operational Efficiency
- Autolus Q2 Revenue Surges 119% to $45.7M; 2026 Guidance Raised to $140–$150M
Financial Snapshot
Short Interest & Short Volume
4.73 days to coverFINRA reported short interest of 8,628,641 shares in AUTL as of the October 30, 2026 settlement, a 4.8% decrease from the prior period — about 4.7 days to cover at its recent average daily volume. On November 20, 2026, 41.7% of AUTL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for AUTL, detected from its recent SEC filings.
Resale Registration for Warrant Shares · No Proceeds to Company
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →